Magnitude and time course of urinary iodine excretion in patients after amiodarone therapy [0.03%]
胺碘酮治疗患者的尿碘排泄量及时间进程
Giulia Marchionni,Giuseppe Pinto,Massimo Locatelli et al.
Giulia Marchionni et al.
Background: Amiodarone is a source of iodine excess that may persist in the body for long time after its withdrawal. The aim of the present analysis was to evaluate the magnitude and long-term time course of 24-h urinary ...
Risk of erythrocytosis in transgender individuals undergoing testosterone therapy: a systematic review [0.03%]
接受雄激素治疗的跨性别男性中发生红细胞增多症的风险：系统性综述
Alberto Scala,Andrea Graziani,Fabrizio Vianello et al.
Alberto Scala et al.
Introduction: In transgender individuals assigned female at birth, testosterone therapy is employed for body masculinization. Guidelines recommend close monitoring for potential side effects of hormonal therapy, especiall...
Semaglutide and obesity: beyond the nutritional and lifestyle intervention? [0.03%]
塞meglutide与肥胖：营养和生活方式干预之外？
Livia Basile,Rossella Cannarella,Stefano Iuliano et al.
Livia Basile et al.
Semaglutide is the second marketed glucagon-like peptide 1 receptor agonist that can be used safely and efficiently in non-diabetic people with excess weight, providing a new milestone in the pharmacological treatment of obesity. This narra...
Combining TSH measurement with TIRADS assessment to further improve the detection of thyroid cancers [0.03%]
联合TSH检测与TI-RADS评估以进一步提高甲状腺癌的检出率
Pierpaolo Trimboli,Marco Curti,Amos Colombo et al.
Pierpaolo Trimboli et al.
Background: Thyroid Imaging Reporting and Data Systems (TIRADSs) have demonstrated high performance in risk stratification of thyroid nodules (TNs). However, further improvements are needed in view of the ongoing project ...
Liraglutide in the management of obesity: real world data (Portugal) [0.03%]
利拉鲁肽在肥胖症治疗中的应用：真实世界数据（葡萄牙）
Carlos Tavares Bello,Inês Redondo Carvalho,Anabela Martins et al.
Carlos Tavares Bello et al.
Background: Overweight and obesity are major public health issues with increasing incidence and prevalence, affecting more than 50% of the population in developed countries. Due to its complex pathophysiology and multifac...
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients [0.03%]
2022年WHO分类对PitNETs多学科管理的临床意义
Miriam Veleno,Antonella Giampietro,Salvatore Raia et al.
Miriam Veleno et al.
The review explores the 2022 update to the World Health Organization (WHO) classification of pituitary adenomas, now referred to as pituitary neuroendocrine tumors (PitNETs), and his possible impact on the clinical management of PitNET pati...
Patrizia Balbinot,Gianni Testino
Patrizia Balbinot
Post-COVID-19 syndrome, inflammation and insulin resistance: a retrospective cohort study [0.03%]
新冠肺炎后症状、炎症和胰岛素抵抗：回顾性队列研究
Patricia Fierro,David Martín,Emilio Pariente-Rodrigo et al.
Patricia Fierro et al.
Background: COVID-19-induced diabetes is a novel and enigmatic disease. Our aim was to evaluate a possible relationship between post-COVID-19 syndrome (PCS) and increased insulin resistance (IR) in non-diabetic outpatient...
How to standardize the diagnostic approach to pituitary neuroendocrine tumors [0.03%]
如何规范垂体神经内分泌肿瘤的诊断途径
Sofia Asioli,Federica Guaraldi,Matteo Zoli et al.
Sofia Asioli et al.
Pituitary tumors present heterogeneous biochemical, clinico-radiological, and histological features. Although histologically benign, a non-negligible number of cases present an unpredictable aggressive behavior with local invasiveness, part...